Literature DB >> 29100029

Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.

Amanda P Schauer1, Craig Sykes2, Mackenzie L Cottrell2, Heather Prince3, Angela D M Kashuba2.   

Abstract

The ability to monitor adherence to antiretroviral therapy is critical for the interpretation of outcomes from clinical studies of HIV, and for optimizing patient care. The antiretrovirals tenofovir (TFV), emtricitabine (FTC), and lamivudine (3TC) are commonly included in drug regimens for HIV prevention and treatment. The active form of the drugs tenofovir diphosphate (TFVdp), emtricitabine triphosphate (FTCtp), and lamivudine triphosphate (3TCtp) are found intracellularly in erythrocytes and peripheral blood mononuclear cells (PBMCs). The ability to collect and analyze dried blood spot (DBS) samples is an attractive alternative to PBMC sampling in many resource limited settings. We developed and validated an assay to quantify all three intracellular metabolites over the range of 100-25000 fmol/sample. This assay utilizes a simple protein precipitation/liquid-liquid extraction of a single 3-mm DBS punch (from a Whatman 903 Protein Saver card) with isotopically labeled 13C5-TFVdp included as the internal standard. Following extraction, samples are analyzed by anion exchange chromatography on a Thermo Biobasic AX 5μm column with detection by electrospray ionization in the positive mode on a AB Sciex API-5000 triple quadrupole mass spectrometer with a total run time of 8min. The assay was linear over the entire range (R2>0.996). The assay was accurate (inter-assay%bias within ±3.0%) and precise (inter-assay % CV≤9.8%). The assay was also reproducible from multiple punches within a spot as well as punches from separate blood spots. Stability was established at room temperature for 3days, and at -80°C for up to 63days. Clinical samples were analyzed from subjects on Truvada®, Stribild®, Descovy®, and Triumeq® regimens and intracellular metabolites were detected in all samples as expected, indicating the assay performs well for all current formulations of TFV, FTC, and 3TC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence monitoring; Antiretroviral; Dried blood spot; HIV; Intracellular metabolite; Validation

Mesh:

Substances:

Year:  2017        PMID: 29100029      PMCID: PMC5741486          DOI: 10.1016/j.jpba.2017.10.030

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  12 in total

Review 1.  Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.

Authors:  Robert S Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Mass Spectrom Rev       Date:  2010-07-08       Impact factor: 10.946

2.  Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.

Authors:  Monica Gandhi; David V Glidden; Albert Liu; Peter L Anderson; Howard Horng; Patricia Defechereux; Juan V Guanira; Beatriz Grinsztejn; Suwat Chariyalertsak; Linda-Gail Bekker; Robert M Grant
Journal:  J Infect Dis       Date:  2015-04-20       Impact factor: 5.226

3.  Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Authors:  Peter L Anderson; Albert Y Liu; Jose R Castillo-Mancilla; Edward M Gardner; Sharon M Seifert; Cricket McHugh; Theresa Wagner; Kayla Campbell; Mary Morrow; Mustafa Ibrahim; Susan Buchbinder; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

Review 5.  Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Authors:  Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

6.  Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

Authors:  Ariane van der Straten; Lut Van Damme; Jessica E Haberer; David R Bangsberg
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

7.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Authors:  Jose Castillo-Mancilla; Sharon Seifert; Kayla Campbell; Stacey Coleman; Kevin McAllister; Jia-Hua Zheng; Edward M Gardner; Albert Liu; David V Glidden; Robert Grant; Sybil Hosek; Craig M Wilson; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors.

Authors:  Zsuzsanna Kuklenyik; Amy Martin; Chou-Pong Pau; Angela Holder; Ae S Youngpairoj; Qi Zheng; Mian-Er Cong; J Gerardo Garcia-Lerma; Walid Heneine; James L Pirkle; John R Barr
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-09-11       Impact factor: 3.205

9.  "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

Authors:  Thomas J Podsadecki; Bernard C Vrijens; Eric P Tousset; Richard A Rode; George J Hanna
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

Review 10.  Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

Authors:  Inge Derdelinckx; Mark A Wainberg; Joep M A Lange; Andrew Hill; Yasmin Halima; Charles A B Boucher
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

View more
  5 in total

1.  Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.

Authors:  Joseph N Mwangi; William M Gilliland; Nicole White; Craig Sykes; Amanda Poliseno; Kelly A Knudtson; Lisa Hightow-Weidman; Angela D M Kashuba; Elias P Rosen
Journal:  Antimicrob Agents Chemother       Date:  2022-03-10       Impact factor: 5.938

Review 2.  The use of dried blood spots for characterizing children's exposure to organic environmental chemicals.

Authors:  Dana Boyd Barr; Kurunthachalam Kannan; Yuxia Cui; Lori Merrill; Lauren M Petrick; John D Meeker; Timothy R Fennell; Elaine M Faustman
Journal:  Environ Res       Date:  2021-01-25       Impact factor: 6.498

3.  Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo.

Authors:  Jennifer L Welch; Hussein Kaddour; Lee Winchester; Courtney V Fletcher; Jack T Stapleton; Chioma M Okeoma
Journal:  J Acquir Immune Defic Syndr       Date:  2020-01-01       Impact factor: 3.771

4.  Preclinical Pharmacokinetics of Lamivudine and Its Interaction with Schisandra chinensis Extract in Rats.

Authors:  Chi-Lin Li; Chen-Hsi Hsieh; Tung-Hu Tsai
Journal:  ACS Omega       Date:  2020-01-22

5.  Simultaneous determination of cardiovascular drugs in dried blood spot by liquid chromatography-tandem mass spectrometry.

Authors:  Hyung Min Kim; Ju-Hwan Park; Nguyen Phuoc Long; Dae-Duk Kim; Sung Won Kwon
Journal:  J Food Drug Anal       Date:  2019-06-26       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.